Biopharma AI
ByIs AI Now Shaping the Future of Biopharma R&D — and Who’s Leading the Transformation?
Executive Summary A recent Endpoints Signal Pulse Report reveals that half of biopharma professionals now consider themselves heavy…
Did NVIDIA Become the Central AI Catalyst for Biopharma in 2025—And Which Players Benefited Most?
2025 marked a pivotal year for artificial intelligence in biopharma. As life sciences companies moved beyond isolated AI…
Which AI Biopharma Startups Truly Won in 2025—And How Did NVIDIA, Big Pharma Collaborations, and Deal Value Define Success?
Executive Perspective 2025 marked a decisive shift for AI biopharma startups—from experimental promise to measurable strategic impact. Success…
Is Nabla Bio Redefining AI-Driven Protein Engineering as Pharma Seeks Faster Paths to Biologics Innovation?
Executive Summary Nabla Bio is emerging as a next-generation AI biotech focused on computationally driven protein and antibody…
Can Unnatural Products and Novartis Unlock “Undruggable” Cardiovascular Targets with AI-Designed Macrocyclic Peptides?
Santa Cruz, Calif., February, 2026 — Unnatural Products, Inc. (UNP) today announced a research collaboration and licensing agreement…
Can Foundation Medicine and Manifold Redefine Precision Oncology Through AI-Driven Genomic Analytics?
Are Foundation Medicine and Manifold Signaling the Next Evolution of AI-Integrated Oncology Intelligence? In a strategic move to…
